Ipamorelin: Mechanism of Action, Evidence & Applications

Ipamorelin is a synthetic pentapeptide of the growth hormone secretagogue (GHRP) class, which stimulates GH release via the GHS-R1a receptor in the pituitary, with high selectivity and minimal effect on ACTH and cortisol.

According to comparative studies, Ipamorelin shows greater selectivity for GH pathway, with less stimulation of ACTH, prolactin and cortisol compared to GHRP-6, as described by Raun et al. (1998).

The GHS-R1a receptor is a G-protein coupled receptor (GPCR) located in the anterior pituitary and hypothalamus. When activated by Ipamorelin, it triggers an intracellular cascade that mobilizes calcium and promotes exocytosis of GH-containing vesicles, stimulating physiological GH release pulses.

The estimated plasma half-life of Ipamorelin is approximately 2 hours in animal models, with peak serum concentration rapidly reached after administration. This short half-life allows for more physiological GH pulses compared to secretagogues with longer half-lives.

One of Ipamorelin's main differentiators is minimal stimulation of non-GH hormones. Studies demonstrate that, unlike GHRP-2 and GHRP-6, Ipamorelin stimulates GH with little effect on ACTH, cortisol and prolactin, offering a more selective hormonal profile.

Ipamorelin is not approved for clinical use in humans in most countries, including the United States, European Union, and Brazil. It is primarily used in clinical and preclinical research contexts. Any discussion of its application should occur with qualified healthcare professionals.

Ipamorelin is a GHRP (short-term GH stimulator), while CJC-1295 is a GHRH (long-term GH stimulator). Together, they act synergistically: GHRH amplifies responsive somatotrophs while GHRP fires the acute pulse, producing greater GH response than either alone.

In preclinical studies, Ipamorelin is typically administered via subcutaneous or intravenous routes. Oral bioavailability is limited due to molecular size (pentapeptide) and gastrointestinal degradation. In research contexts, subcutaneous administration is standard.

Indirectly, yes. Ipamorelin stimulates GH, which then promotes IGF-1 synthesis primarily in the liver. Animal model studies document IGF-1 elevation parallel to GH stimulation. In humans, the magnitude of this response requires further investigation.

In animal studies, GHS-R1a secretagogues like Ipamorelin demonstrate potential increases in lean mass and reductions in visceral fat via the GH-IGF-1 axis. Mechanisms include anabolic effects of GH/IGF-1 and modulation of adipocyte and myocyte differentiation. Extrapolation to humans requires caution.

Pilot studies in humans document acceptable tolerability of Ipamorelin with dose-dependent GH stimulation. Adverse events were generally mild. However, the clinical database is limited compared to more extensively studied secretagogues. Further research on long-term safety is needed.

Tesamorelin is a stabilized GHRH analogue (~30 minute half-life), while Ipamorelin is a GHRP (~2 hours). Both stimulate GH but via different mechanisms: GHRH amplifies somatotrophs, GHRP fires acute pulses. Tesamorelin was approved for HIV lipodystrophy; Ipamorelin remains in research.